Genprex

Monthly Archives: August 2022

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Read More